Newcomb LF, et al. - Investigators assessed 2069 urine specimens collected at baseline, 6, 12, and 24 months in the multi-institutional Canary Prostate Active Surveillance Study (PASS) to analyze the association of urinary PCA3 and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification in subjects with prostate cancer. PCA3 was noted in relation to short-term reclassification at the first surveillance biopsy, after adjusting for PSA, prostate size, and the ratio of biopsy cores with cancer. Conclusively, neither marker nor marker-kinetics were found related with time to reclassification in subsequent biopsies.